Division of Gastroenterology, Hepatology and Endoscopy, Brigham & Women's Hospital, 75 Francis St., Thorn 1404, Boston, MA, 02115, USA.
Harvard Medical School, Boston, MA, 02115, USA.
Surg Endosc. 2017 Dec;31(12):5399-5402. doi: 10.1007/s00464-017-5621-y. Epub 2017 Aug 10.
Chronic abdominal pain can occur after Roux-en-Y gastric bypass (RYGB), and can remain unexplained despite extensive investigation. Bile can pool in the gastric remnant and create a bile reflux gastropathy. The aim of this study was to assess gastric remnant findings in patients with RYGB and chronic abdominal pain of unclear etiology, and to determine the effectiveness of ursodiol therapy for patients with confirmed remnant gastropathy.
All consecutive patients with RYGB and a diagnosis of chronic abdominal pain, and a negative diagnostic workup (including physical examination, routine laboratory work, cross-sectional imaging, and standard upper endoscopy), who underwent device-assisted enteroscopy for evaluation of the gastric remnant, were included. Pathology reports, treatments, and clinical follow-up were recorded.
28 post-RYGB patients (all female) with chronic abdominal pain and negative evaluation were included. Pooling of bile with gastric erythema was noted in 22/28 patients. All 22 patients with endoscopic erythema had pathology consistent with bile reflux chemical gastropathy. Of these patients, 12 were started on a proton pump inhibitor (PPI) alone, and 10 were started on ursodiol. Of the ursodiol group, 8/10 (80%) patients reported substantial improvement or resolution of abdominal pain at clinical follow-up. All three ursodiol patients with repeat endoscopic examination of the gastric remnant had endoscopic and histologic resolution of gastropathy. Of the PPI patients, 1/12 reported improvement in abdominal pain at clinical follow-up (p = 0.002), and both patients with repeat endoscopic examination of the gastric remnant had persistent remnant gastropathy.
Roux-en-Y gastric bypass patients with unexplained chronic pain, and biopsy-confirmed chemical gastropathy, had a significantly higher rate of abdominal pain resolution with ursodiol treatment compared to PPI. Remnant gastropathy due to bile reflux is a treatable cause of chronic abdominal pain in RYGB patients, and ursodiol should be considered for empiric treatment in RYGB patients with unexplained chronic abdominal pain.
Roux-en-Y 胃旁路手术后(RYGB)可能会出现慢性腹痛,尽管进行了广泛的检查,但仍可能无法解释。胆汁可能会在胃残部积聚并导致胆汁反流性胃炎。本研究旨在评估 RYGB 后慢性腹痛且病因不明患者的胃残部发现,并确定对确诊的残胃病变患者使用熊去氧胆酸治疗的效果。
所有 RYGB 后诊断为慢性腹痛且诊断性检查(包括体格检查、常规实验室检查、横断面成像和标准上内窥镜检查)阴性的连续患者均进行设备辅助的胃镜检查以评估胃残部。记录病理报告、治疗和临床随访。
共纳入 28 例 RYGB 后慢性腹痛且评估阴性的患者(均为女性)。22/28 例患者观察到胆汁淤积伴胃红斑。所有 22 例内镜红斑患者的病理均符合胆汁反流性化学性胃炎。这些患者中,12 例单独使用质子泵抑制剂(PPI),10 例使用熊去氧胆酸。熊去氧胆酸组中,8/10(80%)例患者在临床随访时报告腹痛显著改善或缓解。熊去氧胆酸组中 3 例再次接受胃镜检查胃残部的患者内镜和组织学均显示胃炎缓解。PPI 组中,12 例患者中有 1 例(p=0.002)报告腹痛改善,2 例再次接受胃镜检查胃残部的患者仍有残胃病变。
与 PPI 相比,不明原因慢性疼痛且活检证实为化学性胃炎的 RYGB 患者使用熊去氧胆酸治疗的腹痛缓解率明显更高。RYGB 患者由于胆汁反流引起的残胃病变是慢性腹痛的一种可治疗病因,对于不明原因慢性腹痛的 RYGB 患者,应考虑使用熊去氧胆酸进行经验性治疗。